Napo Pharmaceuticals Comments on the Passing of HIV/AIDS Activist and Research Pioneer Dr. Mathilde Krim
January 18 2018 - 8:30AM
Business Wire
Napo Pharmaceuticals, Inc. (Napo), a human health company
developing and commercializing novel gastrointestinal prescription
products from plants used traditionally in rainforest areas, and a
wholly-owned subsidiary of Jaguar Health, Inc. (NASDAQ: JAGX), is
deeply saddened by the passing of Dr. Mathilde Krim, Cofounder and
Chairperson of the American Foundation for AIDS Research (amfAR).
Dr. Krim was a pioneer in HIV research and her contributions have
helped save countless lives and pave the way forward in the fight
against HIV/AIDS.
“As the HIV community mourns the loss of Dr. Krim, we at Napo
would like to recognize her immense contributions to the fight
against HIV. Dr. Krim leaves a long legacy that will continue
onward with the work of amfAR and within the generations that stem
from those whose lives she saved,” stated Lisa Conte, CEO of
Napo.
Dr. Krim, a geneticist and virologist, carved a long and
prestigious history of battling HIV as a scientist, a human rights
activist, philanthropist and educator. Dr. Krim passionately fought
for the rights and anti-stigmatization of people living with HIV,
for legislation regarding expanded access to lifesaving treatment,
for the development of sound, AIDS-related public policies, and
ethical HIV treatment and prevention research.
In 1983, to raise funds for AIDS research, Dr. Krim and others
founded the AIDS Medical Foundation, which later merged with the
National AIDS Research Foundation to form amfAR. From 1990–2004,
she served as amfAR’s chairman of the board.
Over the past 34 years, amfAR has invested over $450 million to
support HIV research and the Foundation’s ground-breaking programs,
such as their Countdown to a Cure Initiative and the amfAR
Institute for HIV Cure Research.
amfAR’s research initiatives have helped advance our
understanding and progress on HIV treatment, prevention, and
epidemiology and greatly contributed to the development of several
new classes of antivirals, including Fusion Inhibitors and CC5
antagonists. amfAR’s early studies of protease inhibitors helped to
revolutionize HIV treatment, resulting in transforming HIV/AIDS
into a treatable disease. amfAR continues to financially support
prevention research to lessen the impact of HIV to the MSM and
transgender communities; support the safe and effective delivery of
HIV treatments in the Asia-Pacific region and conduct vital
research towards the discovery of a scientific basis for an HIV
cure—by the year 2020.
Dr. Krim received her Ph.D. in Geneva, Switzerland in 1953. She
worked as a research scientist at the Sloan-Kettering Institute for
Cancer Research and, from 1981–1985, was the director of its
Interferon Laboratory. She was an adjunct professor of Public
Health and Management at Columbia University’s Mailman School of
Public Health. Dr. Krim was awarded the Presidential Medal of
Freedom in 2002 by President Bill Clinton in recognition of her
"extraordinary compassion and commitment". Shocked by news footage
of Nazi concentration camps in 1945, Dr. Krim joined the Zionist
underground organization Irgun and spent a summer smuggling guns
into France for resistance fighters against British rule over
Palestine.
About Napo Pharmaceuticals, Inc.
San Francisco-based Napo Pharmaceuticals, Inc. (Napo), focuses
on developing and commercializing proprietary human
gastrointestinal pharmaceuticals for the global marketplace from
plants used traditionally in rainforest areas. Napo is a
wholly-owned subsidiary of Jaguar Health, Inc., a commercial stage
natural-products pharmaceuticals company focused on developing
novel, sustainably derived gastrointestinal products for both human
prescription use and animals on a global basis.
For more information about Napo, please visit napopharma.com.
For more information about Jaguar, visit jaguar.health.
Jaguar-JAGX
View source
version on businesswire.com: http://www.businesswire.com/news/home/20180118005477/en/
Jaguar Health, Inc.Peter Hodgephodge@jaguar.health
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Jaguar Health (NASDAQ:JAGX)
Historical Stock Chart
From Jul 2023 to Jul 2024